^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIT D816H

    i
    Other names: KIT, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
    Entrez ID:
    3815
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    3ms
    Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis. (PubMed, Cancers (Basel))
    The KITneg. SM-AHN phenotype was dominated by the heterogeneous AHN (low mast cell burden, presence of additional mutations) with a better median OS of 4.5 years. We conclude that (i) in MCL, negativity for D816V is a relevant prognostic factor and (ii) PSS fail to correctly classify D816Vneg. patients.
    Journal • Metastases
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT D816V • KIT D816H
    3ms
    Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment. (PubMed, Genes (Basel))
    Further studies on the pathobiology of mast cells can lead to clinical improvements, such as better MCT diagnosis and treatment. Our paper reviews studies on the topic of mast cells, which have been carried out over the past few years.
    Review • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • MIR21 (MicroRNA 21) • MIR885 (MicroRNA 885)
    |
    KIT expression • KIT D816H
    over1year
    Novel translocation of POGZ/STK11 in de novo mast cell leukemia with KIT D816H mutation. (PubMed, Leuk Lymphoma)
    No abstract available
    Journal
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation • KIT mutation • KIT D816H
    almost4years
    Design of antitumor drugs targeting c-kit receptor by a new mixed ligand-structure based method. (PubMed, J Mol Graph Model)
    The comparison between the explored ligands and well-known drugs highlights the possibility to overcome tumor-acquired resistance. The best-selected structures (630705 and SML1348) provide valuable binding affinities with the mutated c-Kit forms (respectively T670I and V654A).
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation • KIT T670I • KIT D816H